vs
ENNIS, INC.（EBF）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
ENNIS, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.3倍（$100.2M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 0.4%），ENNIS, INC.自由现金流更多（$15.7M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 1.4%）
ENNIS, INC.是北美领先的商业印刷产品及相关服务供应商，提供定制商业单据、压敏标签、营销宣传物料、促销品、品牌包装等产品，服务覆盖零售、医疗、金融服务及中小企业等多个领域的客户。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
EBF vs PBYI — 直观对比
营收规模更大
EBF
是对方的1.3倍
$75.5M
营收增速更快
PBYI
高出27.3%
0.4%
自由现金流更多
EBF
多$1.3M
$14.4M
两年增速更快
PBYI
近两年复合增速
1.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $100.2M | $75.5M |
| 净利润 | $10.8M | — |
| 毛利率 | 31.9% | 69.3% |
| 营业利润率 | 15.0% | 22.7% |
| 净利率 | 10.8% | — |
| 营收同比 | 0.4% | 27.7% |
| 净利润同比 | 6.1% | — |
| 每股收益（稀释后） | $0.42 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBFPBYI
| Q4 25 | $100.2M | $75.5M | ||
| Q3 25 | $98.7M | $54.5M | ||
| Q2 25 | $97.2M | $52.4M | ||
| Q1 25 | $92.7M | $46.0M | ||
| Q4 24 | $99.8M | $59.1M | ||
| Q3 24 | $99.0M | $80.5M | ||
| Q2 24 | $103.1M | $47.1M | ||
| Q1 24 | $97.4M | $43.8M |
净利润EBFPBYI
| Q4 25 | $10.8M | — | ||
| Q3 25 | $13.2M | $8.8M | ||
| Q2 25 | $9.8M | $5.9M | ||
| Q1 25 | $9.0M | $3.0M | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $10.3M | $20.3M | ||
| Q2 24 | $10.7M | $-4.5M | ||
| Q1 24 | $10.1M | $-4.8M |
毛利率EBFPBYI
| Q4 25 | 31.9% | 69.3% | ||
| Q3 25 | 30.5% | 77.7% | ||
| Q2 25 | 31.1% | 76.5% | ||
| Q1 25 | 29.5% | 77.1% | ||
| Q4 24 | 29.3% | 76.4% | ||
| Q3 24 | 30.1% | 63.9% | ||
| Q2 24 | 30.0% | 77.4% | ||
| Q1 24 | 28.4% | 75.5% |
营业利润率EBFPBYI
| Q4 25 | 15.0% | 22.7% | ||
| Q3 25 | 12.5% | 17.6% | ||
| Q2 25 | 13.7% | 12.7% | ||
| Q1 25 | 13.0% | 8.7% | ||
| Q4 24 | 13.1% | 22.6% | ||
| Q3 24 | 13.3% | 27.4% | ||
| Q2 24 | 13.3% | -4.6% | ||
| Q1 24 | 13.3% | -5.3% |
净利率EBFPBYI
| Q4 25 | 10.8% | — | ||
| Q3 25 | 13.3% | 16.2% | ||
| Q2 25 | 10.1% | 11.2% | ||
| Q1 25 | 9.7% | 6.5% | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 10.4% | 25.2% | ||
| Q2 24 | 10.4% | -9.6% | ||
| Q1 24 | 10.4% | -11.0% |
每股收益（稀释后）EBFPBYI
| Q4 25 | $0.42 | $0.26 | ||
| Q3 25 | $0.51 | $0.17 | ||
| Q2 25 | $0.38 | $0.12 | ||
| Q1 25 | $0.34 | $0.06 | ||
| Q4 24 | $0.39 | $0.40 | ||
| Q3 24 | $0.40 | $0.41 | ||
| Q2 24 | $0.41 | $-0.09 | ||
| Q1 24 | $0.39 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $304.8M | $130.3M |
| 总资产 | $354.3M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资EBFPBYI
| Q4 25 | $31.3M | $97.5M | ||
| Q3 25 | $31.9M | $94.4M | ||
| Q2 25 | $32.6M | $96.0M | ||
| Q1 25 | $72.5M | $93.2M | ||
| Q4 24 | $68.6M | $101.0M | ||
| Q3 24 | $122.6M | $96.7M | ||
| Q2 24 | $123.7M | $96.8M | ||
| Q1 24 | $110.9M | $107.2M |
总债务EBFPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益EBFPBYI
| Q4 25 | $304.8M | $130.3M | ||
| Q3 25 | $305.4M | $115.3M | ||
| Q2 25 | $301.2M | $104.7M | ||
| Q1 25 | $302.0M | $97.1M | ||
| Q4 24 | $297.7M | $92.1M | ||
| Q3 24 | $358.4M | $71.1M | ||
| Q2 24 | $354.4M | $48.5M | ||
| Q1 24 | $349.8M | $51.0M |
总资产EBFPBYI
| Q4 25 | $354.3M | $216.3M | ||
| Q3 25 | $361.8M | $202.9M | ||
| Q2 25 | $361.7M | $194.9M | ||
| Q1 25 | $348.9M | $196.2M | ||
| Q4 24 | $346.1M | $213.3M | ||
| Q3 24 | $406.8M | $220.7M | ||
| Q2 24 | $406.2M | $205.0M | ||
| Q1 24 | $399.2M | $214.1M |
负债/权益比EBFPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.4M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $15.7M | $14.4M |
| 自由现金流率自由现金流/营收 | 15.7% | 19.1% |
| 资本支出强度资本支出/营收 | 0.7% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.52× | — |
| 过去12个月自由现金流最近4个季度 | $42.5M | $41.7M |
8季度趋势，按日历期对齐
经营现金流EBFPBYI
| Q4 25 | $16.4M | $14.4M | ||
| Q3 25 | $10.5M | $9.7M | ||
| Q2 25 | $8.0M | $14.1M | ||
| Q1 25 | $12.8M | $3.6M | ||
| Q4 24 | $18.2M | $15.6M | ||
| Q3 24 | $11.8M | $11.0M | ||
| Q2 24 | $23.1M | $1.0M | ||
| Q1 24 | $16.6M | $11.2M |
自由现金流EBFPBYI
| Q4 25 | $15.7M | $14.4M | ||
| Q3 25 | $9.0M | $9.7M | ||
| Q2 25 | $6.6M | $14.1M | ||
| Q1 25 | $11.1M | $3.6M | ||
| Q4 24 | $17.5M | $15.6M | ||
| Q3 24 | $10.7M | $11.0M | ||
| Q2 24 | $20.6M | $1.0M | ||
| Q1 24 | $15.0M | — |
自由现金流率EBFPBYI
| Q4 25 | 15.7% | 19.1% | ||
| Q3 25 | 9.2% | 17.7% | ||
| Q2 25 | 6.8% | 26.8% | ||
| Q1 25 | 12.0% | 7.7% | ||
| Q4 24 | 17.6% | 26.4% | ||
| Q3 24 | 10.8% | 13.7% | ||
| Q2 24 | 20.0% | 2.1% | ||
| Q1 24 | 15.3% | — |
资本支出强度EBFPBYI
| Q4 25 | 0.7% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | 1.8% | 0.1% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 2.4% | 0.0% | ||
| Q1 24 | 1.7% | 0.0% |
现金转化率EBFPBYI
| Q4 25 | 1.52× | — | ||
| Q3 25 | 0.80× | 1.10× | ||
| Q2 25 | 0.81× | 2.41× | ||
| Q1 25 | 1.41× | 1.21× | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.15× | 0.54× | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
